

RESEARCH

Open Access



# Identifying discrepancies between clinical practice and evidence-based guideline in recurrent pregnancy loss care, a tool for clinical guideline implementation

A. Youssef<sup>1\*</sup>, E.E.L.O. Lashley<sup>1</sup>, N. Vermeulen<sup>2</sup> and M.L.P. van der Hoorn<sup>1</sup>

## Abstract

**Background** Practice variation in recurrent pregnancy loss (RPL) care is common. International guidelines vary in their recommendations for the management of RPL couples, which could lead to an increase of cross border reproductive care. Currently, the Dutch RPL guideline is being adapted from the European Society for Human Reproduction and Embryology (ESHRE) guideline. We aim to identify discrepancies between RPL guidelines and RPL practice. These discrepancies could be considered in the development of a new guideline and implementation strategies to promote adherence to new recommendations.

**Methods** A nationwide survey on the management of RPL patients was conducted across all 107 hospital-based obstetrics and gynaecology practices in the Netherlands. The survey was sent via the Dutch Society for Obstetricians and Gynaecologists to all affiliated clinicians. The questionnaire consisted of 36 questions divided in four sections: clinician's demographics, RPL definition, investigations and therapy. The data were compared to the recommendations given by the Dutch national guideline and the most recent guideline of the ESHRE.

**Results** All hospital-based practices (100%; n = 107) filled in the online questionnaire. The majority of respondents defined RPL similarly, as two or more pregnancy losses (87.4%), not obligatory consecutive (93.1%). More than half of respondents routinely perform thrombophilia screening (58%), although not advised by the ESHRE, while thyroid function (57%), thyroid auto-immunity (27%) and  $\beta$ 2-glycoprotein antibodies (42%) in the context of antiphospholipid syndrome (APS) are recommended but investigated less often. Regarding parental karyotyping, 20% of respondents stated they always perform parental karyotyping, without prior risk assessment, because of RPL. Treatment for hereditary thrombophilia was frequently (43.8% (n = 137)) prescribed although not recommended. And finally, a considerable part (12–16%) of respondents prescribe medication in case of unexplained RPL.

**Conclusion** While many clinicians perform investigations recommended by the ESHRE, there is a considerable variation of RPL practice in the Netherlands. We identified discrepancies between RPL guidelines and RPL practice, providing possibilities to focus on multifaceted implementation strategies, such as educational intervention, local

\*Correspondence:

A. Youssef  
a.youssef@lumc.nl

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

consensus processes and auditing and feedback. This will improve the quality of care provided to RPL patients and may diminish the necessity felt by patients to turn to multiple opinions or cross border reproductive care.

**Keywords** Guidelines, Implementation, RPL, Survey

## Background

Recurrent Pregnancy Loss (RPL) is defined as the loss of two pregnancies before 24th week gestation [1]. Despite extensive investigations, RPL remains unexplained in more than half of couples [1]. This affects couples' psychological health and their quality of life. Therefore, an important role is preserved for the managing physician, to support and guide these couples through the many investigations and treatments.

In previous studies we have shown that although national and international guidelines exist, protocols still vary [1–6]. This high level of practice variation might lead to patients seeking care in various (inter)national centers, and be offered more extensive investigations and treatments.

In the Netherlands, the RPL guideline was published in 2007 by the Dutch Society for Obstetricians and Gynaecologists (NVOG) [7]. In the meantime, new evidence has been published regarding definition, investigations and treatments. Therefore, the guideline is in need of revision, which is currently conducted based on the ESHRE guideline [1]. This ESHRE guideline is developed based on up-to-date evidence with a strict guideline development methodology [8]. To make sure that clinicians will adhere to recommended investigations and treatments, different strategies to implement evidence-based guidelines are suggested [9]. One of the suggested strategies is to audit the current performance of health care providers. In this study we therefore conducted a nationwide cross-sectional survey on current clinical management of RPL patients across all 107 obstetric- and gynecology practices in the Netherlands, and compared the results with the most recent evidence-based guideline developed by the ESHRE.

## Methods

In this cross-sectional survey study an online questionnaire (Castor EDC) was sent to all 107 obstetric- and gynecology practices in the Netherlands in November 2020, with the Leiden University Medical Center as primary research centre. Eight of these hospitals were university hospitals, 62 teaching and 37 non-teaching hospitals. The questionnaire consisted of 36 questions in total which were divided in four sections: clinician's demographics, RPL definition, investigations and therapy (Appendix 1). The survey was conducted over a three months period until all practices had completed the survey at least once (November 2020 until January 2021). The survey was sent via the Dutch Society for

Obstetricians and Gynaecologists (to which all obstetrics and gynaecology practices are adjoined) to all affiliated clinicians. This includes residents, fertility doctors and medical specialists; all respondents participated the same survey. We aimed to obtain at least one response from 75% of all hospitals. After a second invitation to hospitals that had not yet responded, lead clinicians were contacted by mail.

Data is presented as percentages of respondents that indicated the specific answer choice over the total of respondents that answered the question. Between parentheses the number of replies to the corresponding question is given. Data were compared to the Dutch national [7] and the ESHRE [1] recommendations, as currently the ESHRE guideline is being adapted for a new RPL guideline in the Netherlands. Furthermore, data of university hospitals were compared to non-university hospitals using the Chi-squared test, with statistical significance when  $p < 0.05$ .

## Results

### Respondent demographics

All hospital-based practices (100%;  $n=107$ ) filled in the online questionnaire. A total of 446 entries were registered in the online questionnaire database. Of all entries, 315 were returned with 100% completion and 45 questionnaires were returned with at least 50% completion. The participants were primarily gynaecologists (71.7%;  $n=320/446$ ) or obstetrics and gynecology residents (22.4%;  $n=100/446$ ), the remaining participants (5.8%;  $n=26/446$ ) were 24 fertility doctors, one nurse and one medicine student. Half of all questionnaires were returned from non-university teaching hospitals (50.7%;  $n=226/446$ ), 23.1% ( $n=103/446$ ) by non-teaching hospitals and 21.1% ( $n=94/446$ ) by university hospitals. In addition, 20 entries were returned from private clinics and three remained unknown.

### Definition

The majority of respondents defined RPL as two or more pregnancy losses (87.4%;  $n=346/394$ ), not necessarily consecutive (93.1%;  $n=367/394$ ). Ectopic pregnancies (14.8%;  $n=58/393$ ), pregnancy of unknown location (31.3%;  $n=123/393$ ) and molar pregnancies (12.2%;  $n=48/393$ ) were included in the definition of RPL by a minority of respondents and biochemical pregnancies were included in the definition by 45.0% ( $n=177/393$ ) of respondents. Both spontaneous and assisted reproductive technology (ART) pregnancies

were counted in RPL obstetric history by 93.8% of the respondents (n=366/390) (Table 1). The Dutch guideline defines RPL as two or more pregnancy losses before 20 weeks of gestation, excluding ectopic, molar and biochemical pregnancies. The ESHRE guideline includes biochemical pregnancies and pregnancies of unknown location in the definition, as well as ART pregnancies.

### Investigations

The results of the investigations considered in this questionnaire are listed in Table 2, including the recommendations of both the Dutch national guideline and ESHRE. Most respondents initiate investigations after two pregnancy losses (87.3%; n=324/371), and start with obtaining information on general aspects such as body weight and length (93.3%; n=348/373), and lifestyle (90.2%; n=343/373).

According to the questionnaire, approximately 70% of respondents initiate parental karyotyping after risk assessment based upon the maternal age at second miscarriage, number of preceding miscarriages and history of miscarriages in either the siblings or in the parents [10]. 20% responded that they always perform parental

karyotyping. Genetic testing on pregnancy tissue after miscarriages is performed by 2.2% (n=8/363) of respondents. Both guidelines recommend karyotyping only on indication. The ESHRE recommends pregnancy tissue testing only for explanatory purposes.

Almost all participants offer APS investigations (98.9%; n=346/350); lupus anticoagulant and anticardiolipin antibodies (ACA) are generally performed by most participants (see Table 2), anti- $\beta$ 2-glycoprotein antibodies testing is performed by less than half of respondents (IgM testing: 36.9%; n=129/350 and IgG testing: 42.3%; n=148/350). Both guidelines recommend APS testing.

Approximately half of the participants perform Thyroid Stimulating Hormone (TSH) testing (56.5%; n=195/345), and 26.7% performs Thyroid Peroxidase (TPO) antibodies testing (n=92/345). 24% of the participants indicate that they do not perform any endocrine testing (n=107/345). The Dutch guideline does not recommend thyroid screening, while the ESHRE does recommend both function testing and auto-immunity thyroid testing.

Two-dimensional ultrasound was the most performed investigations according to this questionnaire (76.7%; n=266/374). Three-dimensional ultrasound was preferred only by 8.9% of participants (n=31/374). Three-dimensional ultrasound is the preferred technique as mentioned by the ESHRE guideline. The Dutch guideline does not mention testing for uterine malformations.

Regarding the male partner, respondents usually acquired male lifestyle information (60.1%; n=199/331). A minority of responders also performed investigations, such as sperm DNA fragmentation (3.0%; n=10/331) or semen analysis (1.2%; n=4/331). This investigation is recommended by the ESHRE only for explanatory purposes. The Dutch guideline does not mention testing for male factors.

An overview of the adherence to recommended investigations of the ESHRE and Dutch national guideline is provided in Fig. 1.

### Non-recommended investigations

The ESHRE and the Dutch guideline suggests not to screen for hereditary thrombophilia and/or hyperhomocysteinemia, unless in the context of research or in the presence of additional risk factors. Up to 58% (n=206/358) of respondents indicated that they perform some form of thrombophilia investigations, and more than a quarter (29.1%; n=104/358) indicated that they only perform hereditary thrombophilia investigations in case of additional risk factors.

### Treatment

The ESHRE advises to discuss health behaviour modifications such as cessation of smoking, striving for a normal range BMI, and limiting alcohol consumption. Smoking

**Table 1** RPL definition components as used by respondents (in %) with information on the Dutch and ESHRE guideline recommendations for each component

	Number of respondents	Respondents (%)	Dutch guideline	ESHRE guideline
Number	346/396	87	√	√
2	47/396	12		
3	3/396	1		
More than 3				
Consecutiveness	26/394	7	√	√
Consecutive	367/394	93		
Non-consecutive				
Pregnancy type included	383/393	98	√	√
IUG	58/393	15		√
Extra-uterine	48/393	12		√
Molar	177/393	45		
Biochemical PUL	123/393	31		
Origin	24/390	6	*	√
Spontaneous	366/390	94		
ART and spontaneous				
Obstetric history and relationship	226/388	58	√	*
All pregnancies	162/388	42	√	
Only current relationship				

IUG, intra-uterine pregnancy; PUL, pregnancy of unknown location with spontaneous regression

√ Recommended

\* Not indicated

**Table 2** Investigations performed by respondents (in %) with recommendations of the Dutch and ESHRE guideline

Investigations	Number of respondents	Respondents (%)	Dutch guideline	ESHRE guideline
General Aspects	348/373	93	Recommended	Recommended
BMI	343/373	92	Yes	Yes
Lifestyle	93/373	25	Yes	Yes
Blood pressure			*	*
Genetic factors	262/363	72	On indication	On indication
Female karyotype <sup>†</sup>	260/363	72	On indication	On indication
Male karyotype <sup>†</sup>	8/363	2	Not recommended	Explanatory purpose only
Pregnancy tissue array				
Antiphospholipid syndrome	318/350	91	Recommended	Recommended
ACA IgG	294/350	84	Yes	Yes
ACA IgM	321/350	92	Yes	Yes
Lupus Anticoagulant	148/350	42	Yes	Yes
Anti-β2-glycoprotein IgG	129/350	37	*	Yes
Anti-β2-glycoprotein IgM			*	Yes
Endocrine factors	195/345	57	Not recommended	Recommended
TSH	92/345	27	*	Recommended
TPO antibodies	82/345	24	Not recommended	Not routinely recommended
T4 and/or T3	6/345	2	Not recommended	recommended
Progesterone	7/345	2	Not recommended	Not recommended
LH/FSH	51/345	15	Not recommended	recommended
Glucose	29/345	8	Not recommended	Not recommended
HbA1c				recommended
				Not recommended
				recommended
				Not recommended
				recommended
Uterine factors	266/347	77	*	Recommended
2D ultrasound	31/347	9		Preferred
3D ultrasound	11/347	3		technique
HSG	55/347	16		
Hysteroscopy	71/347	21		
SIS	4/347	1		
MRI				
Male investigations	10/331	3	*	Explanatory purpose
Sperm DNA fragmentation	4/331	1		*
Semen analysis	199/331	60		*
Lifestyle				*
Ongoing pregnancy	7/333	2	*	*
hCG	5/333	2	*	
Progesterone	7/333	2	Not recommended	
Pregnancy tissue karyotype	5/333	2	*	
Pregnancy tissue array	270/333	81	Yes	
Ultrasound	2/333	1	*	
HbA1c	5/333	2	*	
Glucose				
Thrombophilia	105/358	29	On indication	Not routinely recommended
Antithrombin – III	83/358	23	Yes	
APC-resistance	37/358	10	Yes	
APTT	80/358	22	*	
Factor II mutation	105/358	29	Yes	
Factor V Leiden	41/358	12	Yes	
Factor VIII	16/358	5	Yes	
Factor X	120/358	34	*	
Protein C	127/358	36	Yes	
Protein S	18/358	5	Yes	
Fibrinogen	9/358	3	*	
INR	20/358	6	*	
Thrombin time	206/358	58	*	
Homocysteine	4/358	1	Yes	
Plasminogen			*	

**Table 2** (continued)

Investigations	Number of respondents	Respondents (%)	Dutch guideline	ESHRE guideline
Infections	9/342	3	*	Not recommended
CMV	17/342	5		recommended
Chlamydia	12/342	4		
Gonorrhoea				
Immunological factors	2/342	1	*	Not recommended
NK-cell plasma level	1/342	0		recommended
NK-cell level in endometrial biopsy	2/342	1		Not recommended
HLA typing and sharing	2/342	1		recommended
HLA antibodies	13/342	4		Not recommended
ANA antibodies				Not recommended
				Explanatory purpose

\* Not indicated

† Number indicated regards percentage of respondents that perform karyotyping according to individual risk assessment table

BMI: Body Mass Index; ACA: Anticardiolipin Antibodies; TSH: Thyroid Stimulating Hormone; TPO: Thyroid Peroxidase; HSG: Hysterosalpingography; SIS: Saline Infusion Sonohysterography; HbA1c: glycated hemoglobin; CMV: Cytomegalovirus; NK: Natural Killer; HLA: Human Leukocyte Antibodies; ANA: Antinuclear Antibodies

cessation was the most given general advice (95.4%; n=310/325), followed by folic acid supplementation (89.2%; n=290/325) and weight loss (78.2%; n=254/325).

Respondents usually treated APS (59.7%; n=190/318) in a next pregnancy, or referred patients for treatment to an internal medicine specialist or haematologist (28.9%; n=92/318). The treatment consisted of Low Molecular Weight Heparin (LMWH) and aspirin, the order and starting time of these medications differed between respondents (such as starting from conception or from fetal heartbeat on ultrasound). The ESHRE recommends in treating patients diagnosed with APS in a next pregnancy with aspirin preconceptionally and LMWH in prophylactic dose starting at the day of a positive pregnancy test.

Treatment of hereditary thrombophilia was given by 43.8% (n=137/313) of respondents and usually consisted of LMWH and/or aspirin. A third of respondents (35.5%; n=111/313) referred patients for such treatment. Uterine septum correction was performed by 12.2% of respondents (n=37/304). Patients with TPO antibodies were treated by half of respondents (51.5%; n=158/307). Thyroid function was followed up during next pregnancy by 43.0% of the respondents (n=132/307). The ESHRE does not recommend treatment for patients with hereditary thrombophilia or uterine septum, and states there is insufficient evidence to treat euthyroid women with thyroid antibodies.

When asked whether any treatments were given to unexplained RPL couples, 16.8% (n=51/303) provided progesterone supplementation and 12.5% (n=38/303) provided aspirin treatment in next pregnancy. A small percentage of respondents also prescribed other experimental treatments for patients with unexplained RPL (Table 3).

An overview of the adherence to recommended treatments of the ESHRE and Dutch guideline is given in Fig. 1.

#### ESHRE guideline


Half of the respondents had knowledge of the existence of the ESHRE guideline (49.3%; n=149/302), and 38.4% (n=116/302) indicated that they have implemented this guideline. University hospitals were more familiar with the ESHRE guideline (61.3% (n=38/62) vs. 46.3% (n=111/240); p=0.035) and used this in daily practice (53.2% (n=33/62) vs. 34.6% (n=83/240); p=0.007). Although a minority already uses the ESHRE guideline, three-quarter of respondents indicated their approval of the Dutch society of gynecology and obstetrics adapting the ESHRE guideline in Dutch practice (74.1%; n=223/301).

#### University versus non-university hospitals

Comparison between university and non-university hospitals showed a statistically significant difference in two questions regarding definition, namely including biochemical pregnancies (57.0% (n=49/86) vs. 41.7% (n=128/307); p=0.012) and the inclusion of couple specific pregnancy losses (27.4% (n=23/84) vs. 45.7% (n=139/304); p=0.003).

Anti- $\beta$ 2-glycoprotein IgG and IgM were investigated more often in university hospitals compared to non-university hospitals (IgG 56.2% (n=41/73) vs. 38.6% (n=107/277) and IgM 49.3% (n=36/73) vs. 33.6% (n=93/277) (p=0.007 and p=0.013).

Both TSH and TPO-antibodies investigations were more often performed in university hospitals (TSH 69% (n=49/71) vs. 53.3% (n=146/274); p=0.017 and TPO-antibodies 36.6% (n=26/71) vs. 24.1% (n=65/274);



**Fig. 1** Representation of the percentage of respondents (Y-axis) that perform RPL care in line with the recommendations of the Dutch Society for Obstetricians and Gynaecologists and the ESHRE for investigations (left part on the X-axis) and treatment (right part on the X-axis). Categories on the X-axis contain all investigations and treatments that are recommended to be performed (non-recommended investigations and treatments are not included in percentages portrayed). General aspects include BMI, lifestyle and blood pressure. General advice refers to advice for smoking cessation, alcohol cessation, weight loss, and folic acid and vitamin D supplementation

$p=0.033$ ). University hospitals also made more often use of 3D ultrasound for the investigation of uterine anomalies (31.9% ( $n=23/72$ ) vs. 2.9% ( $n=8/275$ );  $p<0.001$ ).

Homocysteine screening was performed almost twice as often in non-university hospitals (35.2% ( $n=25/71$ ) vs. 63.1% ( $n=181/287$ );  $p<0.001$ ). Furthermore, thrombophilia screening in the context of scientific studies was performed more often in university hospitals (16.9% ( $n=12/71$ ) vs. 3.8% ( $n=11/287$ );  $p<0.001$ ).

## Discussion

In this cross-sectional survey study we audited the performance of healthcare providers on RPL guideline adherence. We observed that Dutch clinicians generally adhere to advised investigations and interventions (Fig. 1), though there is room for improvement.

In defining RPL, the ESHRE includes biochemical- and resolved pregnancies of unknown location. In our survey, <50% of respondents followed this definition (Table 1), This may lead to an underestimation of RPL and exclusion of patients for further examination and treatment [11].

Considering discrepancies in investigations, we showed that 58% of respondents routinely perform thrombophilia screening, though not advised by the ESHRE [1]. The wide application of this screening can be explained by the long inclusion period of the ALIFE-2 study [12]. In the presence of a thrombophilic factor, clinicians may be tempted to start treatment, explaining the proportion of clinicians indicating treatment of hereditary thrombophilia in RPL couples (Table 3). Regarding parental karyotyping, 20% of respondents stated they

**Table 3** Treatments performed by respondents (in%) with recommendations of the Dutch and ESHRE guideline

	Number of respondents	Re-spondents (%)	Dutch guideline	ESHRE guideline
General advice	310/325	95	Recommended	Recommended
Smoking cessation	217/325	67	Yes	Yes
Alcohol cessation	254/325	78	Yes	Yes
Weight loss	290/325	89	Yes	Yes
Folic acid	142/325	44	*	Yes
Vitamin D			No	Yes <sup>+</sup>
Genetic factors	184/318	58	Recommended	Recommended
Genetic counseling	76/318	24		
PGT				
Uterine factors	37/304	12	Not recommended	Not recommended
Septum resection				
Endocrine antibodies (TPO)	26/307	9	Not recommended	Not recommended
Antiphospholipid syndrome	190/318	60	Recommended	Recommended
Thrombophilia	137/313	44	Not recommended	Not recommended
Unexplained RPL	51/303	17	Not recommended	Not recommended
Progesteron	1/303	0		
hMG	2/303	1		
IVF	3/303	1		
HCG	4/303	1		
Thyroxine	0/303	0		
Corticosteroids	0/303	0		
IVIg	0/303	0		
Intralipids	0/303	0		
LMWH	1/303	0		
Aspirin	23/303	8		
Donor insemination				
Oocyte donation				
Endometrium scratching				
Cross border care referral				

\* Not indicated

<sup>+</sup> Not recommended in the context of improving live birth in RPL couples, but for general health purposes

always perform parental karyotyping, regardless of the risk assessment. Both the Dutch- as the ESHRE guideline recommends risk assessment prior to parental karyotyping, though this risk assessment is different amongst the guidelines, resulting in different number of karyotype testing. Regarding treatment discrepancies, we showed that a substantial portion of respondents advised progesterone or aspirin in patients with unexplained RPL. The ESHRE does not recommend treatment for patients with unexplained RPL, as no significant benefit was shown [13, 14]. A recent trial however showed a possible effect for the use of progesterone in women with  $\geq 3$  pregnancy losses presenting with early bleeding in a next pregnancy [15]. This could have implications for future recommendations on progesterone administration in patients with RPL.

To update the national RPL guideline and increase adherence to evidence-based RPL practice, currently adaptation of the ESHRE guideline is conducted in the Netherlands [1, 7]). While the ESHRE as the Dutch guidelines are similar in some respects, they also contain significant different recommendations either based on data published after finalization of the Dutch guideline, or based on differences in expert opinions in areas with a lack of studies. Implementation of the ESHRE guideline could therefore be hampered. Barriers identified in a European questionnaire [16] were the lack of a Dutch translation and the fact that guidelines are long and difficult to understand. Information on clinical practice with regards to these aspects is helpful to identify discrepancies for better implementation of future evidence-based guidelines.

Recently, Manning et al. have performed a comparable study in the UK and showed equivalent results regarding practice variation [17]. They explained that in many practices dedicated RPL specialists were absent, who can strive for a consistent management of RPL couples. Our results support a similar conclusion based on practice variation between university and non-university clinics. Indeed, university hospitals show more often a definition and policy congruent with the current ESHRE guideline.

We believe that a multifaceted implementation strategy could help improving guideline adherence, and thus evidence-based practice and also reduce unnecessary medical costs [17]. This strategy implies educational intervention, such as disseminating of summary of the recommendations or the development of a web-based tool. In addition, local consensus processes for care that lack scientific evidence could help minimizing practice variation. And finally, auditing of healthcare workers' performance and feedback, as we performed in this study, could act as an incentive to improve a clinician's management of RPL patients. Multifaceted implementation

strategies are however not widely present regarding guideline implementation.

A major strength of our study is that we achieved 100% response rate, as all hospital-based practices have participated in this survey. This resulted in the elimination of sampling bias. Our study confirms previous findings of variation in practice and limited adherence to national guidelines [2, 6, 18, 19]. We showed that ESHRE is rightfully concerned about the implementation of the RPL guideline [20].

A limitation of this study is that it was not possible to elucidate why clinicians persist or refrain from certain investigations and therapeutic options. This could have demonstrated a rationale for the demonstrated practice variation. Furthermore, survey studies are susceptible to desirability bias. It was not possible to measure whether participants gave any desirable answers, knowing guideline recommendations but performing otherwise in daily practice.

## Conclusion

While many clinicians perform investigations recommended by the ESHRE, we also identified considerable discrepancies. Clinicians tend to rely more on guidelines published by national societies. To limit practice variation and thereby delivering care up to maximum standards, it is necessary that efforts of both overarching societies such as the ESHRE and local societies are collaborating in implementation of up-to-date guidelines. Using implementation strategies to improve guideline adherence will ultimately lead to better care delivered to RPL patients.

### List of abbreviations

ACA	Anticardiolipin antibodies
ANA	Antinuclear antibodies
APS	Antiphospholipid syndrome
ART	Artificial reproductive therapy
CRBC	Cross-border reproductive care
ESHRE	European society for human reproduction and embryology
HLA	Human leukocyte antigen
LMWH	Low molecular weight heparin
NVOG	Nederlandse vereniging voor obstetrie en gynaecologie (Dutch Society for Obstetricians and Gynaecologists)
RPL	Recurrent pregnancy loss
TPO	Thyroid peroxidase
VTE	Venous thromboembolism

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12884-023-05869-y>.

Supplementary Material 1

## Acknowledgements

None.

## Authors' contributions

All authors contributed to the methodological development. AY analysed the data. AY wrote the main manuscript text. All authors read and approved the final manuscript.

## Funding

Not applicable.

## Data availability

The datasets generated and analysed during the current study are not publicly available but are available from the corresponding author on reasonable request.

## Declarations

### Ethics approval and consent to participate

Informed consent was obtained from all Participants/ participating persons. The ethical approval was waived by Medical Research Ethics Committee Leiden Den Haag Delft, reference N22.025 according to Medical Research Involving Human Subjects Act (Dutch abbreviation: WMO) does not apply for the above-mentioned study. This study was performed in accordance with the Declaration of Helsinki.

### Consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup>Leiden University Medical Centre, Albinusdreef 2, Leiden 2333 ZA, the Netherlands  
<sup>2</sup>European Society of Human Reproduction and Embryology, Nijverheidslaan 3 (BXL 7 – Gebouw 1), Strombeek, Bever B – 1853, Belgium

Received: 13 November 2022 / Accepted: 23 July 2023

Published online: 28 July 2023

## References

1. The ESHRE Guideline Group on RPL, Bender Atik R, Christiansen OB, Elson J, Kolte AM, Lewis S, et al. ESHRE guideline: recurrent pregnancy loss. *Hum Reprod Open*. 2018;2018(2):hoy004.
2. Youssef A, Vermeulen N, Lashley E, Goddijn M, Van der Hoorn M. Comparison and appraisal of international recurrent pregnancy loss guidelines. *Reproductive biomedicine online*. 2018.
3. Practice Committee of American Society for Reproductive M. Definitions of infertility and recurrent pregnancy loss: a committee opinion. *Fertil Steril*. 2013;99(1):63.
4. Practice Committee of the American Society for Reproductive M. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. *Fertil Steril*. 2012;98(5):1103–11.
5. RCOG. The Investigation and Treatment of Couples with Recurrent First-trimester and Second-trimester Miscarriage. 2011.
6. Youssef A, Lashley E, van der Hoorn M. Richtlijn Herhaalde Miskramen. *Nederlands tijdschrift voor Obstetrie & Gynaecologie*. 2017;130:99–106.
7. NVOG. Recurrent Pregnancy Loss 2007 [08/06/2007]; [Available from: [www.nvog-documenten.nl/richtlijn/doc/download.php?id=750](http://www.nvog-documenten.nl/richtlijn/doc/download.php?id=750)].
8. Vermeulen NLC, Mcheik N, D'Angelo S, Tilleman A, Veleva K, Nelen Z. W. Manual for ESHRE guideline development [PDF]. ESHRE; 2020 [Available from: [https://www.eshre.eu/-/media/sitecore-files/Guidelines/ESHRE\\_Manual\\_Guidelines\\_2020.pdf?la=en&hash=46076BF17F060EAD753F08DF615A2547DC5136C6](https://www.eshre.eu/-/media/sitecore-files/Guidelines/ESHRE_Manual_Guidelines_2020.pdf?la=en&hash=46076BF17F060EAD753F08DF615A2547DC5136C6)].
9. Pereira VC, Silva SN, Carvalho VKS, Zanghelini F, Barreto JOM. Strategies for the implementation of clinical practice guidelines in public health: an overview of systematic reviews. *Health Res Policy Syst*. 2022;20(1):13.
10. Franssen MT, Korevaar JC, Leschot NJ, Bossuyt PM, Knegt AC, Gerssen-Schoorl KB, et al. Selective chromosome analysis in couples with two



- or more miscarriages: case-control study. *BMJ (Clinical research ed)*. 2005;331(7509):137–41.
11. Youssef A, Lashley L, Dieben S, Verburg H, van der Hoorn ML. Defining recurrent pregnancy loss: associated factors and prognosis in couples with two versus three or more pregnancy losses. *Reprod Biomed Online*. 2020;41(4):679–85.
  12. de Jong PG, Quenby S, Bloemenkamp KW, Braams-Lisman BA, de Bruin JP, Coomarasamy A, et al. ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia—study protocol for a randomized controlled trial. *Trials*. 2015;16:208.
  13. de Jong PG, Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. *Cochrane Database Syst Rev*. 2014;(7):Cd004734.
  14. Coomarasamy A, Williams H, Truchanowicz E, Seed PT, Small R, Quenby S, et al. A Randomized Trial of Progesterone in Women with recurrent miscarriages. *N Engl J Med*. 2015;373(22):2141–8.
  15. Coomarasamy A, Harb HM, Devall AJ, Cheed V, Roberts TE, Goranitis I, et al. Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT. *Health technology assessment (Winchester, England)*. 2020;24(33):1–70.
  16. Gabriel AS, Hassold TJ, Thornhill AR, Affara NA, Handyside AH, Griffin DK. An algorithm for determining the origin of trisomy and the positions of chiasmata from SNP genotype data. *Chromosome Res*. 2011;19(2):155–63.
  17. Manning R, Iyer J, Bulmer JN, Maheshwari A, Choudhary M. Are we managing women with recurrent miscarriage appropriately? A snapshot survey of clinical practice within the United Kingdom. *J Obstet gynaecology: J Inst Obstet Gynecol*. 2021;41(5):807–14.
  18. Franssen MT, Korevaar JC, van der Veen F, Boer K, Leschot NJ, Goddijn M. Management of recurrent miscarriage: evaluating the impact of a guideline. *Hum Reprod (Oxford England)*. 2007;22(5):1298–303.
  19. van den Boogaard E, Hermens RP, Franssen AM, Doornbos JP, Kremer JA, van der Veen F, et al. Recurrent miscarriage: do professionals adhere to their guidelines. *Hum Reprod (Oxford England)*. 2013;28(11):2898–904.
  20. Gameiro S, Sousa-Leite M, Vermeulen N. Dissemination, implementation and impact of the ESHRE evidence-based guidelines. *Hum Reprod Open*. 2019;2019(3):hoz011.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.